Suchergebnisse - "Antineoplastic Agents"

PubPharm (16.221)

1

Trends in the approval of cancer therapies by the FDA in the twenty-first century

enthalten in: Nature reviews. Drug discovery | 2023

von Scott, E. | Baines, A. | Gong, Y. | +10

2

FDA Approval Summary : Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Mathieu, L. | Larkins, E. | Sinha, A. | +8

3

Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US

enthalten in: JAMA internal medicine | 2023

von Jazowski, S. | Vaidya, A. | Donohue, J. | +2

4

Preventing, Monitoring, and Managing Ototoxicity Related to Cisplatin : Proactive Rather Than Reactive Approaches Are Needed

enthalten in: JCO oncology practice | 2023

von Mohindra, N.

CommentOn: JCO Oncol Pract. 2023 May;19(5):278-283. - PMID 36921239

5

End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy

enthalten in: JCO oncology practice | 2023

von Dzimitrowicz, H. | Wilson, L. | Jackson, B. | +12

CommentIn: JCO Oncol Pract. 2023 Feb;19(2):70-71. - PMID 36630667

6

The Cost of Metastatic Prostate Cancer in the United States

enthalten in: Urology practice | 2023

von Olsen, T. | Filson, C. | Richards, T. | +2

7

FDA Approval Summary : Belzutifan for von Hippel-Lindau Disease-Associated Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Fallah, J. | Brave, M. | Weinstock, C. | +19

CommentIn: Clin Cancer Res. 2023 Feb 1;29(3):685. - PMID 36722139

8

FDA Approval Summary : Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Baines, A. | Ershler, R. | Kanapuru, B. | +10

9

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Fourie Zirkelbach, J. | Shah, M. | Vallejo, J. | +12

10

The Oncology Care Model and Adherence to Oral Cancer Drugs : A Difference-in-Differences Analysis

enthalten in: Journal of the National Cancer Institute | 2022

von Keating, N. | Brooks, G. | Landrum, M. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[1623]